Rigicon Launches the Conti® Artificial Urinary Sphincter Systems: ContiClassic® and ContiReflex®


Posted May 4, 2020 by melihluleci

Rigicon is globally launching two new artificial urinary sphincter models: ContiClassic® Artificial Urinary Sphincter and ContiReflex® Artificial Urinary Sphincter.

Rigicon announces that ContiClassic® Artificial Urinary Sphincter and the ContiReflex® Artificial Urinary Sphincter models have recently received CE Mark Approval and is initially available in all major European markets. 

ContiClassic® Artificial Urinary Sphincter and ContiReflex® Artificial Urinary Sphincter are implant devices that treat Urinary Incontinence (UI). Conti® Artificial Urinary Sphincter Systems are indicated to treat urinary incontinence due to intrinsic sphincter deficiency in cases such as incontinence following prostate surgery. Conti® Artificial Urinary Sphincter Systems are designed to restore the function of the normal (healthy) urinary sphincter that restricts urine flow out of the bladder.
Conti® Artificial Urinary Sphincter Systems offer unique features for the treatment of Urinary Incontinence. ContiReflex® AUS offers sophisticated intra-abdominal pressure regulation via its innovative pressure-regulating balloon design.

Conti® Artificial Urinary Sphincter Systems are designed to offer decisive solutions to physiological and mechanical problems faced with conventional AUS systems. Both AUS models are designed to reduce urethral erosion and device fluid-loss, the two most common causes of treatment failure.

Conti® Artificial Urinary Sphincter Systems are available in a wide and new range of cuff sizes to offer the best fit to the patient’s urethral anatomy.

All components of the Conti® Artificial Urinary Sphincter Systems are offered with the HydroShield™ hydrophilic coating, giving the physician freedom to choose the aqueous solution dip of choice.

Additionally, the innovative design of the EasyClick™ Y-connectors will facilitate tandem occlusive cuff placement.

Global roll-out of Conti® Artificial Urinary Sphincter Systems will continue through-out 2020.

A multi-center clinical trial, “Evaluation of the Rigicon Conti® Artificial Urinary Sphincter Systems for the Treatment of Patients with Urinary Incontinence (ERASE UI)”, is scheduled for 2020 Q4.

-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Rigicon Media Affiars
Phone 888-202-9790
Business Address 2805 Veterans Memorial Hwy Ste 13
Ronkonkoma, NY 11779
Country United States
Categories Biotech , Health , Medical
Tags urinary incontinence , artificial urinary sphincter , urology , Mens Health , andrology , Stress Incontinence , Incontinence , Bladder Leakage
Last Updated May 4, 2020